NCCN Guidelines for Patients® | Malignant Pleural Mesothelioma - page 60

NCCN Guidelines for Patients
®
Malignant Pleural Mesothelioma, Version 1.2014
58
Index
adjuvant treatment
31–33, 36
anesthesia
16–18, 23, 29, 30
anxiety
39, 43
asbestos
10, 11, 14
biopsy
15–18, 23, 29, 30
cancer cells
7, 10, 16, 29, 31–34
cancer stage
22, 24, 26, 28, 32, 35, 36, 43
cell subtype
22, 25, 26, 28, 32, 36, 43
chemotherapy
29, 31–34, 36, 38, 39
chest wall
6, 23, 24, 38
computed tomography (CT)
15–17, 22, 23, 29, 31–33,
38
diagnose
16, 17
distress
38, 39
extrapleural pneumonectomy (EPP)
31–33, 36
gene
7, 11
imaging test
15, 19, 22, 23, 29, 32
laparoscopy
22, 23
lymph node
7, 23, 24, 29, 30, 32
magnetic resonance imaging (MRI)
22, 23
mediastinoscopy
29
member institutions
57
mesothelium
4, 6–8, 17
metastasis
7
National Comprehensive Cancer Network
1, 2
neoadjuvant treatment
31, 36
panel members
56
pleura
6, 7, 10, 15, 16, 23, 24, 32, 38
pleural biopsy
15–17
pleural cavity
7, 14, 16, 38
pleural effusion
14, 19, 38, 39
pleural mesothelioma
4, 6–8
pleurectomy/decortication (P/D)
31, 32, 36
positron emission tomography (PET)
29, 33, 38
primary treatment
31, 32, 36
radiation therapy
11, 31, 33, 36, 38, 39
risk factor
10
side effect
30, 31, 33, 34, 38, 43
soluble mesothelin-related peptide (SMRP)
15, 17
staging
21–26
supportive care
37–39
surgery
17, 23, 29–36
symptom
14, 29, 32, 38, 39, 43, 44
talc pleurodesis
29, 38, 39
tests
14–19, 22, 23, 26, 29, 30
thoracentesis
15, 16
treatment
27–36, 38, 39
treatment plan
41–45
thoracoscopic biopsy
16, 17, 23
video-assisted thoracoscopic surgery (VATS)
17,
22, 23
Index
1...,50,51,52,53,54,55,56,57,58,59 61,62
Powered by FlippingBook